KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Net Cash Flow (2016 - 2025)

Emergent BioSolutions (EBS) has 16 years of Net Cash Flow data on record, last reported at -$40.1 million in Q4 2025.

  • For Q4 2025, Net Cash Flow rose 21.06% year-over-year to -$40.1 million; the TTM value through Dec 2025 reached $103.4 million, up 1795.08%, while the annual FY2025 figure was $103.4 million, 1795.08% up from the prior year.
  • Net Cash Flow reached -$40.1 million in Q4 2025 per EBS's latest filing, down from -$21.6 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $400.5 million in Q4 2022 and bottomed at -$343.6 million in Q2 2023.
  • Average Net Cash Flow over 5 years is -$20.6 million, with a median of -$36.4 million recorded in 2024.
  • Peak YoY movement for Net Cash Flow: tumbled 638.24% in 2021, then soared 4594.74% in 2024.
  • A 5-year view of Net Cash Flow shows it stood at $172.3 million in 2021, then skyrocketed by 132.44% to $400.5 million in 2022, then plummeted by 93.66% to $25.4 million in 2023, then crashed by 300.0% to -$50.8 million in 2024, then increased by 21.06% to -$40.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Net Cash Flow were -$40.1 million in Q4 2025, -$21.6 million in Q3 2025, and $117.2 million in Q2 2025.